eXoZymes advances cell-free biomanufacturing

eXoZymes is pushing a version of biomanufacturing that removes living cells from the production step and relies instead on engineered enzymes operating in a bioreactor. The Los Angeles-based company says that approach is designed to make rare or hard-to-produce compounds with higher purity and more predictable scale-up than conventional cell-based systems. In recent weeks, the company has tied that pitch to a $2,028,518 NIH grant and to progress on NCT, one of its lead programs. Social-media posts on July 8 and July 9 amplified that message, but the underlying claims come from the company’s own filings and website. ### What is eXoZymes actually saying it does? eXoZymes says its “exozymes” are enzymes engineered with artificial intelligence and bioengineering to function in bioreactors outside living cells. In its SEC filings and investor materials, the company describes the platform as a way to produce chemicals, medicines and nutraceuticals without relying on whole-cell systems. (sec.gov) The company’s website says the platform turns “rare, unscalable, or economically inaccessible chemistry” into “predictable, high-purity production.” It also says freeing enzyme-driven reactions from cells removes a scale-up bottleneck that has limited commercial synthetic biology. Those are company claims, not independent performance benchmarks across the sector. (sec.gov) ### Why does taking living cells out of the process matter? Cell-free biology refers to running biological processes without intact living cells, a concept that has been used for decades in research and is now expanding into manufacturing applications, according to Nature Reviews Genetics and other academic sources. Researchers say cell-free systems can offer tighter control over reactions because they are not constrained by the survival needs of a host cell. (exozymes.com) Mycoplasma contamination in cell-based biomanufacturing can disrupt product quality and trigger costly cleanup, according to a peer-reviewed study on CHO-cell manufacturing. eXoZymes does not publicly quantify contamination reductions from its own platform, but its argument is that producing molecules outside living cells can avoid some of the supply, purity and scale limitations associated with cell-based production. (nature.com) ### Which products is the company using to prove the model? NCT is the company’s lead example. eXoZymes says NCT is a rare natural product aimed first at the over-the-counter market and also being developed for pharmaceutical applications tied to metabolic disease. In an April investor presentation, eXoZymes said it moved NCT from concept to 99% yield and 99.6% purity at 100x scale, with third-party validation, in about one year. (ncbi.nlm.nih.gov) That presentation also says 2026-2027 is an initial commercialization and validation phase focused on compounds that can be positioned as nutraceuticals while showing characteristics that could support pharmaceutical development. (exozymes.com) ### What changed in June and July? On June 24, eXoZymes said it received a Phase IIB Small Business Innovation Research grant from the National Institute of General Medical Sciences, part of the NIH, totaling $2,028,518. The company said the two-year project would begin July 1 and support work on rare cannabinoids and cannabinoid analogs for pharmaceutical evaluation. (exozymes.com) Michael Heltzen, eXoZymes’ chief executive, said in that release that “the hardest part of cannabinoid drug discovery has always been a supply and purity problem” and that the platform is intended to produce naturally occurring cannabinoids and then engineer analogs with better drug-like properties. The company also said total non-dilutive funding awarded to date is now almost $20 million. (sec.gov) ### Where does this sit in the company’s broader timeline? eXoZymes’ April presentation says the company sees 2025-2026 as the period when flagship products and markets are identified and AI enzyme-engineering capabilities are used to expand development. The same presentation places commercial launch and broader commercialization in OTC and pharmaceutical markets in 2026-2027. (sec.gov) Nasdaq-listed eXoZymes has also been raising capital alongside that push. A June 30 prospectus supplement shows the company offered common stock and warrants as part of a public offering, underscoring that its platform claims are being made during an active financing and commercialization phase. (sec.gov) (exozymes.com)